StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) stock

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)

Close on Nov 17, 2026Market cap $51.50MP/E –Yield –

Gain Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Gain Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $10.10M, up 13.9% year over year. For fiscal 2025 it was $10.21M, down 5.4% from the year before. The highest annual figure on record is $11.52M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.21M-5.4%
FY2024Dec 31, 2024$10.79M-6.3%
FY2023Dec 31, 2023$11.52M+37.5%
FY2022Dec 31, 2022$8.38M+16.9%
FY2021Dec 31, 2021$7.16M+217.1%
FY2020Dec 31, 2020$2.26M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.14M-22.5%
Q1 FY2026Mar 31, 2026$2.76M+22.4%
Q4 FY2025Dec 31, 2025$2.35M+91.6%
Q3 FY2025Sep 30, 2025$2.85M+8.7%
Q2 FY2025Jun 30, 2025$2.76M-37.8%
Q1 FY2025Mar 31, 2025$2.26M-10.0%
Q4 FY2024Dec 31, 2024$1.22M-48.4%
Q3 FY2024Sep 30, 2024$2.62M+10.7%
Q2 FY2024Jun 30, 2024$4.44M+11.3%
Q1 FY2024Mar 31, 2024$2.51M-10.2%
Q4 FY2023Dec 31, 2023$2.37M+4.4%
Q3 FY2023Sep 30, 2023$2.37M+20.5%
Q2 FY2023Jun 30, 2023$3.99M+54.4%
Q1 FY2023Mar 31, 2023$2.79M+79.3%
Q4 FY2022Dec 31, 2022$2.27M+54.4%
Q3 FY2022Sep 30, 2022$1.96M-20.7%
Q2 FY2022Jun 30, 2022$2.58M+44.0%
Q1 FY2022Mar 31, 2022$1.56M+9.5%
Q4 FY2021Dec 31, 2021$1.47M+50.9%
Q3 FY2021Sep 30, 2021$2.48M+479.4%
Q2 FY2021Jun 30, 2021$1.79M+308.7%
Q1 FY2021Mar 31, 2021$1.42M+240.7%
Q4 FY2020Dec 31, 2020$975.61K–
Q3 FY2020Sep 30, 2020$427.47K–
Q2 FY2020Jun 30, 2020$438.87K–
Q1 FY2020Mar 31, 2020$417.26K–

More Gain Therapeutics figures

See a number that looks wrong?